← Back to Search

Device

FETO Therapy for Diaphragmatic Hernia (FETO Trial)

N/A
Recruiting
Led By Anthony Johnson, DO
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Pregnant women age 18 years and older
Isolated Left CDH with liver up
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after insertion of balloon to delivery- (from 27 weeks gestational age up to 39 weeks gestational age)
Awards & highlights

FETO Trial Summary

This trial is testing a new fetal treatment for left Congenital Diaphragmatic Hernia. If successful, it could be used in future trials with more patients.

Who is the study for?
This trial is for pregnant women over 18 with a single pregnancy and severe left Congenital Diaphragmatic Hernia (CDH) in the fetus. Eligible participants must have an LHR less than 30%, be able to stay near the hospital, and not have any conditions that risk mother or baby during surgery.Check my eligibility
What is being tested?
The study tests Fetoscopic Endoluminal Tracheal Occlusion (FETO) therapy's safety and feasibility on fetuses with severe CDH. It's a preliminary study at UTHealth to see if they can join larger multi-center trials later.See study design
What are the potential side effects?
Potential side effects are not explicitly listed but may include risks associated with fetal surgeries such as preterm labor, complications from anesthesia, infection, or harm to the fetus.

FETO Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am pregnant and 18 years or older.
Select...
My condition involves a left-sided diaphragmatic hernia with the liver positioned higher.

FETO Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at delivery
This trial's timeline: 3 weeks for screening, Varies for treatment, and at delivery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Gestational age at delivery
Successful placement of Balt Goldbal2 balloon
Successful removal of Balt Goldbal2 balloon
Secondary outcome measures
Lung head ratio
Lung volume
Survival at 30 days
Other outcome measures
Maternal complications

FETO Trial Design

1Treatment groups
Experimental Treatment
Group I: FETO therapyExperimental Treatment1 Intervention
Intervention name: FETO therapy

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
914 Previous Clinical Trials
324,342 Total Patients Enrolled
Anthony JohnsonLead Sponsor
Anthony Johnson, DOPrincipal Investigator - The University of Texas Health Science Center, Houston
Saint Anthony Central Hospital
Medical School - Northeast Ohio Medical University
University of Texas Health Science Center, San Antonio, Residency in Otolaryngology - Head & Neck Surgery

Media Library

FETO therapy (Device) Clinical Trial Eligibility Overview. Trial Name: NCT02596802 — N/A
Congenital Diaphragmatic Hernia Research Study Groups: FETO therapy
Congenital Diaphragmatic Hernia Clinical Trial 2023: FETO therapy Highlights & Side Effects. Trial Name: NCT02596802 — N/A
FETO therapy (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02596802 — N/A
~4 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top